Perhaps you think it's impossible to score another 1,000% gain off this "tech titan" stock. Think again. An unusual strategy lets you virtually "recreate" gains off the biggest companies you thought had come and gone. CLICK HERE to see how it works.
Cardinal Health, Inc. (NYSE:CAH): Stock of the Day
by David Fessler, Advisory Panelist, Investment U
When we think of industrial suppliers, W.W. Grainger (NYSE:GWW) is one of the largest in the business. From nuts and bolts to janitorial supplies, it’s a good bet
Grainger’s can supply it. The company consolidates parts, equipment and supplies from thousands of manufacturers and provides customers with one-stop shopping, both on its website and from its huge four inch thick catalog.
Grainger’s has been bucking the trend and doing reasonably well during this business contraction. However it did acknowledge that business conditions in 2009 will be challenging, and its first quarter sales will be significantly lower than last quarter.
As dismal as that sounds Grainger should be one of the first to benefit from the upswing when it comes. Motors, fans, bearings and a host of other parts used in industrial and manufacturing environments still break, wear out and need to be replaced.
I’ve written about the company in more detail on several occasions in this space, and you can read my articles here. I still believe it is a good addition to any long-term well-balanced energy and infrastructure portfolio.
But did you know that there’s a Grainger-like company that serves the healthcare industry? Cardinal Health, Inc. (NYSE:CAH) is an $87 billion global manufacturer, supplier and distributor to the healthcare industry.
Cardinal makes over 50,000 critical customer deliveries every day. Its 40,000 customers – located on five continents – include medical centers, hospitals, retail and mail order pharmacies, health clinics and numerous other healthcare providers.
Cardinal is so big, 33% of all delivered medical products, drugs, and laboratory supplies pass through the company’s supply chain.
It also is the largest source for special nuclear pharmaceutical drugs. It delivers more than 13 million doses annually to outpatient facilities and hospital nuclear medicine departments.
The company has grown both organically and through acquisitions, completing two of them in 2008.
And while spending delays by hospitals in 2009 have prompted the company to lower its current year outlook, it chalked up some impressive results for its fourth fiscal quarter:
Net income jumped to 93 cents a share from 90 cents a year ago. Revenue was up 7.8% to $25.1 billion, slightly beating analyst’s estimates.
Chairman and Chief Executive R. Kerry Clark remarked that he is seeing the first signs of credit markets beginning to thaw, and that has him cautiously optimistic: “Despite a very challenging economic climate, we had solid growth from both of our primary operating segments.”
As a result, Cardinal reaffirmed its 2009 full year guidance, and claims it expects full-year top-line growth of 6-7%.
In the face of an uncertain economy, a global healthcare supplier like Cardinal might be a good choice for those wishing to establish a solid footing, in what is likely to be a tumultuous year for investing.
- AmerisourceBergen Corporation: Increase the “Health” of your Portfolio
- Healthcare Stocks… Are They Truly Recession-Proof?
- Cornell Companies Inc. (NYSE: CRN): Stock of the day
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
David Fessler is an Advisory Panelist for Investment U and The Oxford Club, one of the world’s most exclusive and prestigious networks of private investors.
Investment U RSS Feed